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Abstract 
Over the last 15 years, there has been a steady increase in the 
development of orphan medicinal products (OMPs). This raises an 
important question: What impact does the EU marketing authorisation of 
an OMP have on related research? This article establishes that the key 
orphan incentive, namely the 10-year market exclusivity provision laid 
down in Article 8 of the EU Regulation on OMPs (Regulation 141/2000), 
has a huge potential impact on related research. It is argued that this 
provision can make it too difficult for researchers/sponsors to attain 
marketing approval for closely related products. This article advances 
two proposals to address this problem. First, it argues for new principles 
for assessing similarity, so as to clarify and narrow the ambit of market 
exclusivity. Secondly, it argues for improved conditions for a 
demonstration of ‘clinical superiority’ for similar OMPs. 
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1 Introduction  
EU Regulation 141/2000 on orphan medicinal products (OMPs) was 
                                                          
*  We would like to thank Robert Schütze for his advice on the general principles of EU 
law and Emma Cave for her helpful comments. We remain responsible for any errors. 
 introduced to promote investment in the research and development of 
medicines to treat patients suffering from rare diseases, i.e., conditions 
that affect not more than five in 10,000 people in the EU.
1
 An 
EU Regulation, in contrast to an EU Directive, is directly applicable in all 
EU Member States and does not need to be transposed into national law.
2
 
Since the Regulation’s introduction, there has been a steady increase in 
the number of marketing authorisations for OMPs in the EU.
3
 From 2000 
to 2015, the European Commission authorised a total of 114 OMPs to be 
marketed in the EU for the benefit of rare disease patients.
4
 However, this 
represents only a small proportion of the 1,596 orphan designations 
granted by the European Commission during the same period.
5
 This 
significant discrepancy between the number of medicinal products 
designated as OMPs (1,596) and the number of OMPs authorised (114) 
illustrates that it is difficult in practice to obtain an EU marketing 
authorisation. This is not the result of a single factor, but regulatory 
complexity is, in particular, burdensome for not-for-profit organisations 
and small and medium-sized enterprises (SMEs), which have scarce 
human and financial resources and only limited regulatory expertise.
6
 
Overly challenging requirements are likely to hinder the availability of 
new medicines; including those that fulfil ‘unmet medical needs’, which 
a Commission Regulation defines as those medicines that address ‘a 
condition for which there exists no satisfactory method of diagnosis, 
prevention or treatment’ approved in the EU or those that would 
otherwise ‘be of major therapeutic advantage to those affected’.
7
 The 
currently authorised OMPs in the EU, for example, only cover one 
percent of the 5,000 to 8,000 different types of rare diseases.
8
 If the 
                                                          
1  European Commission, ‘Orphan Medicinal Products’, online at 
ec.europa.eu/health/human-use/orphan-medicines/index_en.htm, retrieved 11 January 
2017. See also Regulation 141/2000, Art. 3(1)(a).  
2  See TFEU, Art. 288. 
3  European Commission, ‘Inventory of Union and Member State Incentives to Support 
Research into, and the Development and Availability of, Orphan Medicinal Products – 
State of Play 2015’, SWD (2015) 13 Final, 22 February 2016, pp. 4, 20. 
4  See European Medicines Agency, 2016, ‘Orphan Medicines Figures’, p. 9, online at 
www.ema.europa.eu/docs/en_GB/document_library/Other/2015/04/WC500185766.pdf, 
retrieved 11 January 2017. 
5  Ibid., pp. 1, 6. 
6  This is the case even though there are additional incentives for SMEs, including 
administrative and procedural assistance and fee reductions. See European Medicines 
Agency, ‘Orphan Incentives’, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000
393.jsp, retrieved 11 January 2017.  
7  Commission Regulation 507/2006, Art. 4(2). 
8  Supra note 3, p. 4. 
 regulatory structure is to successfully incentivise both innovation in 
human medicines and high standards of quality, safety and efficacy, then 
the relevant provisions need to be regularly updated in the light of 
scientific and technical developments. 
In response to these problems, the European Commission has initiated 
a number of reforms that are relevant for OMPs. In July 2016, it launched 
a review of Commission Regulation 847/2000 on the concept of ‘similar 
medicinal product’.
9
 In November 2016, it published a Commission 
notice on the application of Articles 3, 5 and 7 of Regulation 141/2000 on 
OMPs,
10
 which replaces a Commission Communication from 2003.
11
  
The European Medicines Agency (EMA) has also initiated four 
developments. First, following the publication of the new Commission 
notice, the EMA updated its post-authorisation guidance on, in particular, 
extensions of marketing authorisations for OMPs.
12
 Secondly, it 
introduced a scheme in March 2016 aimed at strengthening support for 
the development of medicinal products that have the potential to fulfil 
unmet medical needs.
13
 Thirdly, the EMA is developing a framework to 
enhance collaboration with academia by helping academic researchers to 
understand the regulatory environment and to translate their research 
results into new medicinal products.
14
 Fourthly, together with the United 
States Food and Drug Administration (FDA), the EMA has set up a new 
‘cluster’ on rare diseases that focuses on the sharing of information on 
the scientific evaluation and development of medicines for rare diseases, 
                                                          
9  See European Commission, ‘Concept of “Similar Medicinal Product” in the Context of 
the Orphan Legislation: Adaption to Technical Progress’, 29 July 2016, online at 
ec.europa.eu/health/files/orphanmp/2016_07_pc_orphan/2016_07_consultation_paper.p
df, retrieved 11 January 2017. 
10 See Commission Notice (2016/C 424/03). 
11 See Commission Communication on Regulation 141/2000 (2003/C 178/02).  
12  EMA, ‘European Medicines Agency Post-Authorisation Procedural Advice for Users 
of the Centralised Procedure’, EMEA-H-19984/03 Rev. 67, 19 December 2016, ss. 3 
and 4. See also EMA, ‘Regulatory Information – New Guidance on Type II Variations 
and Marketing Authorisation Extensions for Orphan-Designated Medicines’, 
18 November 2016, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/11/news_
detail_002645.jsp&mid=WC0b01ac058004d5c1, retrieved 11 January 2017. 
13 PRIME (PRIority MEdicines): EMA, ‘Launch of PRIME – Paving the Way for 
Promising Medicines for Patients’, 7 March 2016, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/03/news_
detail_002484.jsp&mid=WC0b01ac058004d5c1; see also EMA, ‘PRIME: Priority 
Medicines’, online at 
www.ema.europa.eu/ema/index.jsp%3Fcurl%3Dpages/regulation/general/general_conte
nt_000660.jsp%26mid%3DWC0b01ac058096f643, retrieved 11 January 2017. 
14 EMA, ‘Developing a Framework of Collaboration Between the European Medicines 
Agency (EMA) and Academia’, EMA/424858/2016, 1 August 2016.  
 including clinical trials in small populations.
15
  
In addition, reforms are likely in the field of Advanced Therapy 
Medicinal Products (ATMPs). An ATMP is defined
16
 as a biological 
medicinal product that can be classified as either: (i) a gene therapy 
medicinal product (GTMP),
17
 (ii) a somatic cell therapy medicinal 
product (sCTMP),
18
 (iii) a tissue engineered product (TEP),
19
 or (iv) a 
combined ATMP.
20
 In June 2016, the EMA published a report from a 
multi-stakeholder meeting held in May 2016 that contains specific 
proposals to foster ATMP development and authorisation in Europe.
21
 
The report proposes, for example, more ATMP-specific guidance from 
regulators and greater harmonisation between the EU Member States on 
several aspects of the ATMP regulatory framework, such as the 
implementation of the hospital exemption laid down in Article 28(2) of 
Regulation 1394/2007.
22
 Together with the European Commission and 
the competent national authorities, the EMA is currently discussing the 
feasibility of the report’s proposals to determine appropriate actions.
23
 
This article will focus on the marketing authorisation of OMPs and 
                                                          
15 EMA, ‘EU-US Collaboration to Boost Medicine Development for Rare Diseases’, 
26 September 2016, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/09/news_
detail_002609.jsp&mid=WC0b01ac058004d5c1, retrieved 11 January 2017. 
16 Regulation 1394/2007, Art. 2(1). 
17 Defined in Annex I, Part IV of Directive 2001/83/EC. E.g., a ‘solution of recombinant 
AAV2 vectors supplied in a vial’ (used to treat ‘inherited retinal degeneration due to 
autosomal recessive RPE65 gene mutations’); see EMA, ‘Scientific Recommendation 
on Classification of Advanced Therapy Medicinal Products’, EMA/291899/2016, 
25 April 2016. 
18 Defined in Annex I, Part IV of Directive 2001/83/EC. E.g., ‘autologous T cells in 
injectable saline suspended in a cryopreservation medium’ (used to treat Epstein-Barr 
Virus positive malignancies); see EMA, ‘Scientific Recommendation on Classification 
of Advanced Therapy Medicinal Products’, EMA/291907/2016, 25 April 2016. 
19 Defined in Art. 2(1)(b) of Regulation 1394/2007 as a product that (i) contains or 
consists of engineered tissues or cells; and (ii) is presented as having properties to be 
administered to human beings with a view to repairing, regenerating or replacing human 
tissue. It may contain tissues or cells of animal or human origin (whether viable or 
non-viable) and additional substances (scaffolds or matrices). E.g., ‘a suspension of 
autologous blood cells, contained in a syringe’ (used to treat critical limb ischemia); see 
EMA, ‘Scientific Recommendation on Classification of Advanced Therapy Medicinal 
Products’, EMA/291914/2016, 25 April 2016. 
20 Defined in Art. 2(1)(d) of Regulation 1394/2007. Combined ATMPs incorporate one or 
more medical devices as an integral part of the product. E.g., cells embedded in a 
scaffold or biodegradable matrix.  
21 EMA, ‘Advanced Therapy Medicines: Exploring Solutions to Foster Development and 
Expand Patient Access in Europe’, EMA/345874/2016, 3 June 2016.  
22 Ibid., pp. 5, 7, 8, 10. 
23 Ibid., p. 10.  
 address the following question: What impact does the EU marketing 
authorisation of an OMP have on the development and marketing of 
closely related products? The analysis will begin by explaining the 
EU regulatory context, namely the criteria for orphan designation and the 
centralised authorisation procedure. It will then give an overview of the 
range of orphan incentives (i.e., incentives that are offered in the EU for 
OMPs) and examine the most important of these: the 10-year market 
exclusivity provision laid down in Article 8 of Regulation 141/2000. To 
answer the question we have just posed, the analysis will make use of a 
real-life example: Holoclar is an ATMP and OMP, and the first stem 
cell-based medicinal product approved for use in the EU. In this way, we 
will also draw attention to often overlooked aspects of the regulatory 
scheme applying to stem cell research.
24
  
This article will establish that the principle of market exclusivity has a 
huge potential impact on related research, making it too difficult for 
researchers/sponsors
25
 to obtain an EU marketing authorisation for 
closely related products. We will make two proposals to address the 
identified problem without losing the benefits of the market exclusivity 
provision. First, we will propose new principles for assessing similarity. 
Our analysis will go beyond the European Commission’s proposals of 
29 July 2016 and give particular emphasis to the criterion of ‘same 
therapeutic indication’. In particular, we will argue that in cases where 
there is an overlap of the target populations, a medicinal product should 
be considered (compared to a currently authorised OMP) as follows: 
(i) with regard to the overlap, it is intended for the same therapeutic 
indication; and (ii) where there is no overlap of the target populations, the 
medicinal product has a different therapeutic indication. Secondly, we 
will propose improved conditions for a demonstration of ‘clinical 
superiority’ in relation to Article 3(3)(d) of Commission 
Regulation 847/2000. Our proposal will give effect to the aim of orphan 
incentives, i.e., to support research, development and marketing with 
regard to OMPs. 
 
                                                          
24 Cf., e.g., S. Devaney, Stem Cell Research and the Collaborative Regulation of 
Innovation (Abingdon, Oxon: Routledge, 2014), which makes no mention of 
Regulation 141/2000. 
25 A sponsor is defined in Art. 2(c) of Regulation 141/2000 as ‘any legal or natural 
person, established in the Community, seeking to obtain or having obtained the 
designation of a medicinal product as an orphan medicinal product’. 
 2 The EU Regulatory Context: Orphan Designation and the 
Centralised Authorisation Procedure 
For a medicinal product to be marketed within the EU as an OMP, it must 
first receive ‘orphan designation’ and then ‘marketing authorisation’.26 
Three criteria must be met for orphan designation. First, the medicinal 
product must be intended for the prevention, diagnosis or treatment of a 
condition that is ‘life-threatening’ or ‘chronically debilitating’.
27
 
Secondly, the condition must affect not more than five in 10,000 people 
in the EU (prevalence criterion) or it must be improbable that the 
marketing of the medicinal product in the EU ‘would generate sufficient 
return to justify the necessary investment’ (profitability criterion).
28
 
Thirdly, there must be ‘no satisfactory method of diagnosis, prevention or 
treatment of the condition in question’ already approved in the EU or, if 
there is such a method, the medicinal product must ‘be of significant 
benefit to those affected by that condition’.
29
 The term ‘significant 
benefit’ is defined as ‘a clinically relevant advantage or a major 
contribution to patient care’.
30
 Thus, orphan designation is available for 
medicinal products aimed at addressing an evidenced clinical need with 
regard to severe, rare conditions. 
Procedurally, an application for orphan designation must be submitted 
to the EMA before the marketing authorisation application is made.
31
 The 
Committee for Orphan Medicinal Products (COMP) is tasked with 
examining and making recommendations on these applications within 90 
days.
32
 The European Commission then makes its final decision within 
30 days of receipt of the COMP opinion.
33
 A medicinal product that is 
designated as an OMP is entered in the Community Register of Orphan 
Medicinal Products.
34
 From 2000 to 2015, a total of 1,596 medicinal 
products have been designated as OMPs by the European Commission.
35
 
The most common designated orphan conditions include cystic fibrosis, 
multiple myeloma, acute myeloid leukaemia, chronic lymphoblastic 
                                                          
26 A medicinal product is defined in Art. 2(a) of Regulation 141/2000 as ‘a medicinal 
product for human use, as defined in Article 2 of Directive 65/65/EEC’. 
27 Regulation 141/2000, Art. 3(1)(a).  
28 Ibid.  
29 Ibid., Art. 3(1)(b).  
30 Commission Regulation 847/2000, Art. 3(2).  
31 Regulation 141/2000, Art. 5(1). 
32 Ibid., Arts. 4 and 5(5). 
33 Ibid., Art. 5(8).  
34 Ibid., Art. 5(9). For the removal from the register see Art. 5(12). 
35 Supra note 4, pp. 1, 6. 
 leukaemia, pancreatic carcinoma ovarian cancer and glioma.
36
 However, 
an orphan designation is not a marketing authorisation, which means that 
the quality, safety and efficacy of the medicinal product still needs to be 
demonstrated.  
The marketing of medicinal products within an EU Member State 
requires authorisation by the competent authorities of that Member State 
or, in some case, by the European Commission.
37
 Since 20 November 
2005, marketing authorisation for OMPs has been granted by the 
European Commission, i.e., they have been subject to the centralised 
authorisation procedure that is carried out by the EMA.
38
 Before this 
date, 22 OMPs had been authorised through the centralised procedure and 
two OMPs through national procedures.
39
 A total of 128 OMPs have 
been approved to date by the European Commission for the benefit of 
rare disease patients.
40
 A centralised marketing authorisation is valid for 
five years on a renewable basis throughout the EU.
41
  
Under the centralised authorisation procedure, there is the possibility 
of submitting a request for an ‘accelerated assessment’ and a ‘conditional 
marketing authorisation’.
42
 These regulatory tools in European legislation 
allow patients to gain early access to new medicinal products that address 
unmet medical needs.
43
 An accelerated assessment procedure allows for a 
faster evaluation of an application for a marketing authorisation of a 
medicinal product that is ‘of major interest from the point of view of 
public health and in particular from the viewpoint of therapeutic 
innovation’, i.e., the time-limit is reduced from a maximum of 210 days 
to 150 days.
44
 A conditional marketing authorisation may be granted on 
                                                          
36 Supra note 3, p. 3.  
37 Directive 2001/83/EC, Art. 6(1). A medicinal product is defined in Art. 1(2). 
38 Regulation 726/2004, Arts. 3(1), 90 and Annex 4. 
39 Supra note 3, pp. 4, 21–23.  
40 Status as of 11 January 2017. Supra note 1. 
41 See Regulation 726/2004, Arts. 13(1) and 14(1)-(3). See also EMA, 2015, ‘Applying 
for EU Marketing Authorisation’, online at 
www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2011/03/WC500104233.pd
f , retrieved 11 January 2017. 
42 Regulation 726/2004, Art. 14(7) and (9). Other possibilities are a request for a 
marketing authorisation under exceptional circumstances under Art. 14(8) of 
Regulation 726/2004 or a request for a CHMP compassionate use opinion under Art. 83 
of that Regulation. 
43 EMA, ‘Fast Track Routes for Medicines That Address Unmet Medical Needs’, 27 July 
2015, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/07/news_
detail_002381.jsp&mid=WC0b01ac058004d5c1, retrieved 11 January 2017. 
44 Regulation 726/2004, Arts. 14(9) and 6(3), subpara. 1.  
 the basis of less complete clinical data than is usually required for a 
medicinal product that belongs to a particular category, including OMPs, 
and fulfils certain requirements such as a positive risk-benefit balance 
and unmet medical needs.
45
 Such authorisation is valid for one year, on a 
renewable basis.
46
 It will convert into a ‘standard’ marketing 
authorisation as soon as the applicant provides comprehensive data.
47
 
To optimise the process of such key regulatory tools, the EMA has 
recently revised its guidelines on the implementation of ‘accelerated 
assessment’ and ‘conditional marketing authorisation’.
48
 The revised 
guidelines came into effect on 1 June 2016 and provide more detailed 
guidance on how to justify fulfilment of the legal requirements and 
emphasise the importance of early dialogue with EMA.
49
  
 
3 Market Exclusivity: Impact on Related Research 
3.1 Orphan Incentive: The Principle of Market Exclusivity  
As mentioned earlier, a total of 128 OMPs have been authorised by the 
European Commission for the benefit of patients with rare diseases, but 
this covers only one per cent of those diseases. Orphan incentives are 
crucial to promoting investment in this field. The current orphan 
incentives include reduction of fees or fee waivers; scientific advice and 
protocol assistance; grants (such as Horizon 2020 and its call ‘New 
Therapies for Rare Diseases’); access to the centralised authorisation 
procedure and 10 years of market exclusivity in the EU.
50
  
The key orphan incentive is the market exclusivity provision laid 
down in Article 8 of Regulation 141/2000. This provides that marketing 
authorisation shall not be granted for a 10-year period for a second 
                                                          
45 Ibid., Art. 14(7); Commission Regulation 507/2006, Arts. 2 and 4.  
46 Regulation 726/2004, Art. 14(7). 
47 See EMA, ‘Conditional Marketing Authorisation’, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000
925.jsp&mid=WC0b01ac05809f843b, retrieved 11 January 2017. 
48 EMA, ‘Guideline on the Scientific Application and the Practical Arrangements 
Necessary to Implement the Procedure for Accelerated Assessment Pursuant to 
Article 14(9) of Regulation 726/2004’, EMA/CHMP/671361/2015 Rev. 1, 
25 February 2016; EMA, ‘Guideline on the Scientific Application and the Practical 
Arrangements Necessary to Implement Commission Regulation 507/2006 on the 
Conditional Marketing Authorisation for Medicinal Products for Human Use Falling 
Within the Scope of Regulation 726/2004’, EMA/CHMP/509951/2006, Rev.1, 
25 February 2016. 
49 Ibid.; supra note 43.  
50 See Regulation 141/2000, Arts. 6–9. See also supra note 6.  
 medicinal product ‘for the same therapeutic indication, in respect of a 
similar medicinal product’.
51
 Where a paediatric investigation plan is 
completed, the period of market exclusivity may be extended to 
12 years.
52
 
The market exclusivity provision does not apply where a second 
medicinal product is not similar to an authorised OMP. The definition of 
‘similar medicinal product’ is therefore a decisive factor in the granting 
or refusal of marketing authorisation for a second medicinal product and 
this is provided by the key implementing legislation: Commission 
Regulation 847/2000. A medicinal product is defined as similar if (a) it 
contains ‘a similar active substance’ and (b) ‘is intended for the same 
therapeutic indication’ as the currently authorised OMP.
53
  
A ‘similar active substance’ is an active substance (i.e., ‘a substance 
with physiological or pharmacological activity’)
54
 that is either identical 
or has ‘the same principal molecular structural features (but not 
necessarily all of the same molecular structural features) and which acts 
via the same mechanism’.
55
 Specific examples are provided, such as the 
same radiopharmaceutical active substance. 
The ‘same therapeutic indication’ is not defined in either 
Regulation 141/2000 or Commission Regulation 847/2000. The 
Commission has, however, provided guidance. A Commission Guideline 
clarifies that the therapeutic indication of an OMP is set by the marketing 
authorisation and must be subsumed under the (usually broader) 
designated orphan condition.
56
 In cases where the therapeutic indication 
authorised through the marketing approval procedure is a subset of the 
designated condition, the marketing authorisation holder (MAH) for the 
original OMP will benefit from a 10-year period of market exclusivity for 
this medicinal product, for this approved indication.
57
 
There are, however, three derogations from market exclusivity, where 
a marketing authorisation may be granted to a similar medicinal product 
                                                          
51Regulation 141/2000, Art. 8(1), emphasis added. Under Art. 8(2) of 
Regulation 141/2000, the period of market exclusivity can be reduced to six years if it is 
established at the end of the fifth year that the criteria for designation under Art. 3 are 
no longer fulfilled.  
52 Regulation 1901/2006, Art. 37. 
53 Commission Regulation 847/2000, Art. 3(3)(b). 
54 Ibid., Art. 3(3)(a). 
55 Ibid., Art. 3(3)(c), emphasis added. 
56 Commission Guideline 2008/C 242/08, Guideline on aspects of the application of 
Article 8(1) and (3) of Regulation (EC) No 141/2000: Assessing similarity of medicinal 
products versus authorised orphan medicinal products benefiting from market 
exclusivity and applying derogations from that market exclusivity, s. 2.3, para. 1. 
57 Supra note 10, s. D.1. 
 for the same therapeutic indication. These are specified by Article 8(3) of 
Regulation 141/2000 and will be examined below in relation to a real-life 
example.  
In sum, subject to three derogations, the MAH for an OMP will have a 
10-year period of market exclusivity over the OMP, during which any 
‘similar medicinal product’ cannot be put on the EU market. Three 
criteria must be taken into consideration, when assessing the similarity 
between a second medicinal product and an authorised OMP: 
(1) principal molecular structural features, (2) mechanism of action and 
(3) therapeutic indication. If there are significant differences within one 
or more of these criteria, then the second medicinal product will be 
considered as not similar to the authorised OMP,
58
 and the second 
applicant could then obtain marketing authorisation for their own 
medicinal product.  
We will now seek to show that the derogations and the criteria for a 
similar medicinal product sometimes hinder the rationale for granting 
market exclusivity, namely, incentivising research and development of 
medicines to treat patients suffering from rare diseases. 
 
3.2 Impact on Related Research 
The impact of EU marketing authorisation of an OMP on related research 
can best be illustrated by looking at a real-life example. Holoclar is the 
first stem cell-based medicinal product approved for use in the EU.
59
 The 
product was given conditional marketing authorisation by the European 
Commission on 17 February 2015.
60
 Holoclar’s active substance is: ‘Ex 
vivo expanded autologous human corneal epithelium cells containing 
stem cells’
61
 and its approved indication is:  
 
Treatment of adult patients with moderate to severe limbal stem cell 
deficiency (defined by the presence of superficial corneal 
neovascularisation in at least two corneal quadrants, with central 
corneal involvement, and severely impaired visual acuity), unilateral 
                                                          
58 Supra note 56, s. 2.  
59 For product information see EMA, ‘Holoclar’, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002450/hu
man_med_001844.jsp&mid=WC0b01ac058001d124, retrieved 11 January 2017. 
60 MA number: EU/1/14/987. See Commission Implementing Decision of 
17 February 2015, C(2015)1028(final).  
61 European Commission, ‘Community Register of Medicinal Products for Human Use’, 
online at ec.europa.eu/health/documents/community-register/html/h987.htm, retrieved 
11 January 2017. 
 or bilateral, due to physical or chemical ocular burns. A minimum of 
1-2 mm
2
 of undamaged limbus is required for biopsy.
62
  
 
Limbal stem cell deficiency (LSCD) is a condition that is 
characterised by the loss or dysfunction of corneal epithelial stem cells 
(CESCs), also known as limbal stem cells, i.e., stem cells that can be 
found in the basal layer of the limbal epithelium.
63
 LSCD may result 
from a variety of causes such as hereditary diseases, inflammatory 
diseases, chemical or thermal burns and contact lens related eye 
disease.
64
 When the CESCs are destroyed or absent or when the stem cell 
niche is damaged, clinical symptoms can include pain, irritation, tearing 
and extreme sensitivity to light.
65
 In addition, it can lead to a process 
resulting in significant visual impairment and even total blindness.
66
 
Holoclar has been designated an OMP and an ATMP.
67
 Its designated 
orphan condition is: ‘Treatment of corneal lesions, with associated 
corneal (limbal) stem cell deficiency, due to ocular burns’.
68
 The MAH 
for Holoclar benefits from orphan market exclusivity for a 10-year period 
from 19 February 2015.
69
 
Applying the regulatory conditions outlined above, assessing the 
similarity between a second medicinal product and Holoclar requires 
                                                          
62 Ibid.  
63 S. Ahmad, F. Figueiredo and M. Lako, ‘Corneal Epithelial Stem Cells: 
Characterization, Culture and Transplantation’, Regenerative Medicine 1(1) (2006) 29–
44; S. Kolli et al., ‘Successful Application of Ex Vivo Expanded Human Autologous 
Oral Mucosal Epithelium for the Treatment of Total Bilateral Limbal Stem Cell 
Deficiency’, Stem Cells 32(8) (2014) 2135–2146; see also 
http://youtu.be/qUQRhxjtbpQ, retrieved 11 January 2017. 
64 S. Kolli et al., ‘Corneal Epithelial Stem Cells and Their Therapeutic Application’, in: 
H. Baharvand (ed.), Trends in Stem Cell Biology and Technology (New York: Humana 
Press, 2009) pp. 319, 338.  
65 Ibid., pp. 319, 338, 339. 
66 This process is known as ‘conjunctivalisation’: Ibid., pp. 319, 339.  
67 See EMA, ‘Summaries of Scientific Recommendations on Classification of Advanced 
Therapy Medicinal Products’, online at 
www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000
301.jsp&mid=WC0b01ac05800862c0 and European Commission, ‘Community 
Register of Orphan Medicinal Products’, online at 
ec.europa.eu/health/documents/community-register/html/o579.htm, retrieved 
11 January 2017.  
68 European Commission, supra note 67. 
69 See supra note 61. This applies provided that the MAH for Holocar (i.e., Chiesi 
Farmaceutici S.P.A.) completes the post-approval measures for the conditional approval 
under Art. 14(7) of Regulation 726/2004, i.e., to carry out study HLSTM03 (due date: 
December 2020). See further EMA, ‘Assessment Report’, EMA/25273/2015, 
18 December 2014, pp. 79-81.  
 consideration of whether the second medicinal product contains a ‘similar 
active substance’ and is intended for the ‘same therapeutic indication’ as 
Holoclar. The three criteria – principal molecular structural features, 
mechanism of action and therapeutic indication – must therefore be taken 
into account and any significant differences with regard to one or more of 
these criteria will mean that the second medicinal product is not similar 
to Holoclar. Only if this is the case (i.e., the second product is not 
similar), may it be marketed within the EU without reliance on one of the 
three derogations from Holoclar’s market exclusivity. 
Consider a second medicinal product that consists of ex vivo 
expanded human autologous oral mucosal epithelium and is intended to 
be used to treat patients with total bilateral LSCD.
70
 It seems to us that 
such product would not be similar to Holoclar. Regardless of whether the 
active substance is similar,
71
 the second medicinal product is intended for 
a different therapeutic indication. The approved indication of Holoclar 
does not cover the treatment of total bilateral LSCD since Holoclar 
requires a minimum of 1-2 mm
2
 of undamaged limbus for biopsy. 
Consequently, in our view, the 10-year market exclusivity provision laid 
down in Article 8 of Regulation 141/2000 would not apply in this case 
and thus would not prevent the granting of marketing authorisation to 
such a second product.  
It is, however, not difficult to imagine a situation for which the 
assessment of similarity becomes more complex. Let us consider the 
example of another medicinal product designated as an OMP and an 
ATMP that includes ex vivo expanded autologous human CESCs and is 
intended for the treatment of total unilateral LSCD in both adult and child 
patients.
72
 This medicinal product contains a ‘similar active substance’,
73
 
                                                          
70 An example for such a product is: S. Kolli et al., supra note 63. 
71 It is difficult in practice to assess whether an active substance is similar under the 
definition in Art. 3(3)(c) of Commission Regulation 847/2000. However, the European 
Commission has stressed in its consultation document concerning the revision of the 
definition of ‘similar active substance’ that two related cell-based medicinal products 
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S. Kolli et al., supra note 63. 
72 An example of such a product is: S. Kolli et al., ‘Successful Clinical Implementation of 
Corneal Epithelial Stem Cell Therapy for Treatment of Unilateral Limbal Stem Cell 
Deficiency’, Stem Cells 28(3) (2009) 597-610. 
73 As per the definition in Commission Regulation 847/2000, Art. 3(3)(c). 
 because Holoclar consists of ex vivo expanded autologous human corneal 
epithelial cells containing CESCs. It is therefore crucial to assess whether 
it is intended for the ‘same therapeutic indication’. The approved 
indication of Holoclar (quoted above) covers the treatment of ‘adult 
patients with moderate to severe’ LSCD ‘due to physical or chemical 
ocular burns’. It therefore does not cover (i) patients under 18 years, 
(ii) milder forms of LSCD, or (iii) LSCD due to causes other than 
physical or chemical ocular burns.
74
  
The alternative medicinal product we are considering is intended to be 
used to treat patients of all ages with total unilateral LSCD, including 
such due to physical or chemical ocular burns. There is therefore an 
overlap of the target populations for the two OMPs with regard to adult 
patients with total unilateral LSCD due to physical or chemical ocular 
burns. The Commission Guideline says that, in cases overlap of target 
populations, the extent of overlap will be a decisive factor for 
determining whether a second medicinal product has a different 
therapeutic indication to an authorised OMP.
75
 In the case of a designated 
OMP, as here, the competent assessing body will be the Committee for 
Medicinal Products for Human Use (CHMP) at the EMA.
76
  
If the CHMP concludes in the present case that the overlap of the 
target populations is not significant and that therefore the second 
medicinal product and Holoclar are intended for different therapeutic 
indications and are not similar, the European Commission will grant a 
marketing authorisation to the second medicinal product, provided that its 
quality, safety and efficacy are shown. Since the second medicinal 
product is designated as an OMP, the MAH of such a product will then 
benefit from a 10-year period of market exclusivity for that product for 
the approved indication. As stated earlier, this period will be extended to 
12 years if a paediatric investigation plan is completed.  
If, however, the CHMP considers the overlap of the target populations 
significant and thus that the two products are similar, the situation is very 
different. Then, the second applicant may only place the second 
medicinal product on the EU market if able to rely on one of the 
derogations from market exclusivity. 
Article 8(3) of Regulation 141/2000 contains three derogations from 
the market exclusivity: (a) consent of the MAH for the original OMP to 
the second applicant, (b) the inability of the MAH for the original OMP 
‘to supply sufficient quantities of the medicinal product’, and (c) the 
second applicant can demonstrate that the second medicinal product, 
                                                          
74 See also EMA, supra note 69, p. 66.  
75 Supra note 56, s. 2.3, para. 2. 
76 Ibid., ss. 3.1, 3.4. 
 though similar to the authorised OMP, is ‘safer, more effective or 
otherwise clinically superior’.
77
  
In the case under discussion, the second applicant will have difficulty 
establishing any of these. The first two options are in the sphere of 
influence of the MAH, rather than the second applicant. The third, (c), is 
hard to prove in practice. ‘Clinically superior’ is defined to mean that a 
second medicinal product is shown to have a significant diagnostic or 
therapeutic advantage over an authorised OMP in at least one of three 
specified ways: (i) ‘greater efficacy’; (ii) ‘greater safety in a substantial 
portion of the target population(s)’; and (iii) in exceptional 
circumstances, where neither (i) nor (ii) has been shown, a demonstration 
that the second ‘medicinal product otherwise makes a major contribution 
to diagnosis or to patient care’.78 Demonstrating a significant diagnostic 
or therapeutic advantage over and above that provided by Holoclar (such 
as greater efficacy or greater safety in a substantial portion of the target 
population) usually requires direct comparative clinical trials.
79
 But the 
small patient population poses practical hurdles for conducting clinical 
trials on OMPs, for example, they must often be carried out in multiple 
centres in multiple countries.
80
 At the time of Holoclar’s designation as 
an OMP, its target population was estimated to be ‘approximately 0.3 in 
10,000 people’ in the EU, which is considerably below the threshold of 
five in 10,000 people set by Regulation 141/2000 and amounts to only 
around 15,000 people in the entire European Economic Area.
81
 
Moreover, although the manufacturing process of Holoclar includes the 
use of material from animals (lethally-irradiated murine 3T3 fibroblast 
cells and foetal bovine serum), it will be difficult – even for a second 
applicant whose product is totally animal free and manufactured in 
compliance with Good Manufacturing Practice – to show ‘greater safety 
in a substantial portion of the target population(s)’, since no adverse 
effects derived from the use of such material have been reported over the 
last 30 years.
82
  
                                                          
77 Regulation 141/2000, Art. 8(3). 
78 Commission Regulation 847/2000, Art. 3(3)(d). 
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80 For further information see EMA, ‘Guideline on Clinical Trials in Small Populations’, 
Doc. Ref. CHMP/EWP/83561/2005, 27 July 2006. 
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82 Commission Regulation 847/2000, Art. 3(3)(d)(2). For Holoclar's ingredients see EMA, 
‘EPAR Product Information’, p. 4, online at 
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 If the CHMP concludes that the second medicinal product is similar to 
Holoclar and that none of the three options arise, it will recommend the 
refusal of marketing approval. This seems to us to be a real possibility, 
because there is a clear overlap of target populations and the derogation 
provisions are either outside the control of the second applicant or present 
an almost insurmountable hurdle in practice. This example supports our 
contention that the marketing authorisation of an OMP, or more 
precisely, the market exclusivity provision laid down in Article 8 of 
Regulation 141/2000, has a huge potential impact on related research. In 
practice, it will be extremely difficult for some researchers/sponsors to 
obtain a marketing authorisation for their product. 
 
4 Amending Proposals 
The laudable aim of orphan incentives is to promote investment in the 
research and development of OMPs in order to ensure that patients 
suffering from rare diseases have the same quality of treatment as other 
patients.
83
 We maintain that the problems we have identified can be 
addressed in a way that is consistent with this aim without repeal of the 
10-year market exclusivity provision. Before advancing our suggestions 
for amending proposals, we will first explain why the solution cannot rest 
with national exemptions from the central authorisation. 
4.1 Harmonisation of the National Exemptions 
There may be the option for some researchers/sponsors of an ATMP to 
apply for a national exemption in the respective EU country. 
Article 28(2) of Regulation 1394/2007 introduces the so-called ‘hospital 
exemption’, whereby it is permissible under specific conditions to 
manufacture and supply an ATMP without an EU marketing 
authorisation by the European Commission.
84
 The hospital exemption 
                                                                                                                                  
For an example of a product that is totally animal free and manufactured in compliance 
with GMP see supra note 72. For further information on the issue of xenogeneic 
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Current Treatment Options and Emerging Therapies’, Stem Cells International (2016) 
1-22. 
83 Supra note 3, p. 2. 
84 See also Directive 2001/83/EC, Art. 3(7). ATMPs are usually subject to the centralised 
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 scheme is regulated on a national level and effectively applies to products 
that are produced on a one-off ad hoc basis for the treatment of an 
individual patient in accordance with a specific medical prescription. In 
Germany, for example, the hospital exemption is laid down in section 4b 
of the German Medicinal Products Act.
85
 In contrast in the UK, there are 
two national schemes available for ATMPs: (1) the hospital exemption in 
regulation 171 of the Human Medicines Regulations 2012/1916 and 
(2) the ‘specials exemption’ in regulation 167 of the same Regulations, 
which allows for the supply of an ATMP under certain requirements to 
fulfil a patient’s ‘special needs’.
86
  
In our view, however, the solution to the identified problems does not 
rest with national exemptions. First, the UK specials exemption, for 
example, will probably not apply to the cases under discussion, because 
the special needs test requires that there is no equivalent approved 
medicinal product available that can fulfil the special needs of the patient 
in question.
87
 Secondly, the hospital exemption is exclusively for ATMPs 
and does not apply in cases of an OMP that is not designated as an 
ATMP at the same time. Thirdly, even if the requirements of a hospital 
(or specials) exemption in the respective EU Member State are met, an 
ATMP under such a national scheme would only be available to a small 
number of patients instead of all patients in Europe (as in the event of an 
EU marketing authorisation). Thus, even though the national exemptions 
would certainly benefit from harmonisation (cf. German hospital 
exemption with the UK hospital and special exemptions),
88 
such reforms 
could not address the problems identified.  
4.2 New Principles for Assessing Similarity 
Above we highlighted some difficulties with the concept of a ‘similar 
medicinal product’ in Article 3(3)(b) of Commission 
Regulation 847/2000, which requires consideration of whether the second 
medicinal product contains a similar active substance and is intended for 
the same therapeutic indication. It seems to us that both limbs would 
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 benefit from revision of their respectively definitions. 
4.2.1 Similar Active Substance  
The European Commission, in a consultation document released on 
29 July 2016, has itself recognised the need to revisit the first limb of the 
definition. It proposes two amendments to Commission 
Regulation 847/2000: the first is to repeal the definition of ‘active 
substance’ in Article 3(3)(a) and the second is to revise the definition of 
‘similar active substance’ in Article 3(3)(c).
89
 
In principle, we welcome the first proposal. Since ‘active substance’ 
now has a more precise and detailed definition in Article 1(3a) of 
Directive 2001/83/EC, there is no need for the definition in 
Article 3(3)(a) of Commission Regulation 847/2000. The consultation 
document argues that Article 8(4) of Regulation 141/2000 expressly 
empowers the Commission to adopt definitions of ‘similar medicinal 
product’ and ‘clinical superiority’ in an implementing Regulation, but 
‘does not empower the Commission to define the term “active 
substance”’.
90
 With respect, it seems to us that such a power is implied. If 
it is permissible for the Commission to define ‘similar medicinal product’ 
by reference to an ‘active substance’, then it must be permissible for the 
Commission Regulation to provide or refer to a definition of ‘active 
substance’. The drawback of the Commission’s proposal is that since 
Directive 2001/83/EC is transposed into national law, EU Member States 
have a degree of leeway as to the exact definition to be adopted. This 
creates the possibility of divergence in the ambit of market exclusivity 
that is not tied to its rationale. In our view, it would be better if 
Article 3(3)(a) of Commission Regulation 847/2000 is not repealed but 
revised. Instead of providing its own definition of ‘active substance’, 
Article 3(3)(a) should define the term by reference to Article 1(3a) of the 
Directive. This approach has the advantage that the Commission 
Regulation is directly applicable in all EU Member States. A single 
definition among all Member States would contribute to a greater level of 
consistency and legal certainty. This proposal does not, as it might 
appear, undermine the decision of the European Parliament and the 
Council to place the definition on active substance in a Directive, rather 
than a Regulation, because our proposal would mean that the Directive’s 
definition is only directly applicable within the scope of Commission 
Regulation 847/2000. 
We fully support the European Commission’s second proposal for 
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 change. The definition of ‘similar active substance’ in Article 3(3)(c) of 
Commission Regulation 847/2000 requires adaption to technical 
progress.
91
 We do not propose to review the specific recommendations of 
the Commission here beyond noting that the proposed updates will 
address advances in the field of biological medicinal products including 
ATMPs and, by contributing to greater legal certainty, will make it easier 
for researchers/sponsors to predict whether an active substance will be 
considered similar under the current definition. We therefore welcome 
the Commission’s effort to consult the public and stakeholders on its 
proposal regarding the highly technical definition in Article 3(3)(c).  
4.2.2 Same Therapeutic Indication 
We saw above (in 3.2) that in cases of related research where a second 
medicinal product contains a similar active substance to that contained in 
an authorised OMP, the therapeutic indication will be decisive to the 
assessment of whether two related medicinal products are similar. We 
sought to demonstrate the difficulties presented when applying the 
Commission Guideline to the effect that, in the event of an overlap of the 
target populations, the extent of that overlap will be a crucial factor to 
conclude that two medicinal products are intended for the same 
therapeutic indication.
92
 It remains unclear when such overlap should be 
considered significant, i.e., when the competent assessing body is likely 
to come to the conclusion that a second medicinal product is intended for 
the same therapeutic indication. Such uncertainty as to whether 
researchers/sponsors will, after investing considerable time and effort in 
developing an OMP, be allowed to bring their product on the EU market 
does not promote the development of OMPs and is thus contrary to the 
aim of orphan incentives. 
Encouraging investment in the research and development of OMPs 
requires transparency, consistency and appropriate predictability in the 
procedure for assessing similarity. If the principle for assessing the ‘same 
therapeutic indication’ criterion is retained, so the focus in cases of an 
overlap of the target populations remains on the extent of such overlap, 
clear guidance on when the competent assessing body should consider an 
overlap significant is needed. Indeed, for clarity, the European 
Commission should provide specific examples of significant overlaps of 
the target populations in the Commission Guideline. These examples 
should be updated at regular intervals to take account of scientific and 
technical developments. 
                                                          
91 Ibid., p. 1. 
92 Supra note 56, s. 2.3, para. 2. 
 Clarifying statements of this type would contribute to a more 
transparent and consistent procedure for assessing similarity, but would 
not address the underlying problem. Applicants for a marketing 
authorisation for a second medicinal product would still depend on the 
interpretation by the competent assessing body as to whether it considers 
the overlap significant. Consequently, our preferred proposal is to 
abandon the need to assess the extent of the overlap of the target 
populations. Instead, we recommend that market exclusivity should be 
strictly tied to the approved target population of the OMP. That is to say, 
two medicinal products should only be regarded as intended for the same 
therapeutic indication in the area of overlap of the target populations. 
This would mean that where there is no overlap of the target populations, 
the two medicinal products would be regarded as having different 
therapeutic indications. We will now explain this further by applying it to 
the example above. 
Holoclar and the second medicinal product have an overlap of target 
populations because both are intended to apply to adult patients with total 
unilateral LSCD due to physical or chemical ocular burns. Consequently, 
these two medicinal products would be regarded as having the same 
therapeutic indication with regard to that target population. This would 
mean the second medicinal product is, in this respect, similar to Holoclar. 
It follows that the second medicinal product could not be placed on the 
EU market during the 10-year period of market exclusivity for Holoclar 
for the treatment of adult patients with total unilateral LSCD due to 
physical or chemical ocular burns, unless one of the three derogations in 
Article 8(3) of Regulation 141/2000 applied. 
Where there is no overlap of the target populations – i.e., for the 
treatment of patients with total unilateral LSCD due to causes other than 
physical or chemical ocular burns – the two medicinal products would be 
regarded as having different therapeutic indications. Since it is assumed 
that, in the present case, the second medicinal product is intended to be 
used to treat both adults and children (i.e., patients under the age of 
18 years) with total unilateral LSCD, the second medicinal product also 
has a different therapeutic indication to Holoclar with regard to the 
treatment of children with total unilateral LSCD due to physical or 
chemical ocular burns. It follows that the CHMP would consider the 
second medicinal product – in this regard – as not similar to Holoclar. 
Consequently, provided that the quality, safety and efficacy of the second 
medicinal product could be shown, the European Commission could 
grant a marketing authorisation to the second medicinal product for the 
following therapeutic indication: Treatment of adult patients with total 
unilateral LSCD due to causes other than physical or chemical ocular 
 burns and treatment of children with total unilateral LSCD, including 
such due to physical or chemical ocular burns. The marketing 
authorisation holder (MAH) of the second OMP would then benefit from 
market exclusivity for that product for that approved indication.  
This proposal has three main advantages compared to the current 
criterion for assessment of ‘same therapeutic indication’. First, it ensures 
a transparent and consistent assessment procedure. The clear division 
between overlap (= same therapeutic indication) and no overlap 
(= different therapeutic indications) simplifies the process. It makes the 
outcome predictable and thus contributes to greater planning security for 
researchers and sponsors of OMPs. Secondly, it produces a ‘win-win 
situation’: the MAH of the authorised OMP, the researcher/sponsor of the 
second medicinal product and the patients in Europe would benefit from 
our proposed approach. Applied to the example, the MAH for Holoclar 
would retain the benefit of market exclusivity for the approved indication 
until 19 February 2025.
93
 In addition, the second medicinal product could 
be placed on the EU market to treat adult patients with total unilateral 
LSCD due to causes other than physical or chemical ocular burns and to 
treat children with total unilateral LSCD, including such due to physical 
or chemical ocular burns. The MAH of the second OMP would benefit 
himself from market exclusivity for that product for that approved 
indication. In contrast, there is only an ‘all or nothing’ solution under the 
current approach. Either the second medicinal product can be put on the 
EU market to treat patients with total unilateral LSCD (including such 
due to physical or chemical ocular burns) or not, depending on whether 
the CHMP considers the overlap of the target populations significant. 
Moreover, patients (adults and children) in Europe suffering from total 
unilateral LSCD due to causes other than physical or chemical ocular 
burns and children suffering from total unilateral LSCD due to physical 
or chemical ocular burns would gain access to the second 
product/treatment, which could cure their rare disease. Thirdly, our 
proposal is consistent with the aim of orphan incentives, because it 
encourages investment in the research and development of OMPs. 
In order to implement our proposed approach, the Commission 
Guideline would need to be revised accordingly. In particular, we suggest 
that section 2.3 could be formulated as follows:
94
  
The therapeutic indication of an orphan medicinal product is set by 
the marketing authorisation and must be subsumed under the 
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 (usually broader) designated orphan condition. If there is an overlap 
of the target populations, a medicinal product will be considered 
(compared to a currently authorised orphan medicinal product) as 
intended for the same therapeutic indication with regard to the 
overlap and otherwise considered to have a different therapeutic 
indication. This means that if the therapeutic indication of a 
currently authorised orphan medicinal product is A and the 
therapeutic indication of a medicinal product is A+B, then the two 
products will have the same therapeutic indication regarding A and 
different therapeutic indications regarding B. 
 
Specific examples of various types of medicinal products (e.g., chemical 
medicinal products, biological medicinal products and 
radiopharmaceutical medicinal products) should additionally be provided.  
4.3 Article 8(3)(c) of Regulation 141/2000 – Exception for Similar 
OMPs 
We also argued above (in 3.2) that a second applicant, whose medicinal 
product is a designated OMP and similar to an authorised OMP, will have 
difficulty establishing that one of the three derogations in Article 8(3) of 
Regulation 141/2000 applies. The first two derogations (consent or 
inability to supply sufficient quantities) are in the sphere of influence of 
the MAH for the original OMP, rather than the second applicant. The 
third derogation is hard to demonstrate in practice, even though it is in 
the hands of the second applicant to establish that the second medicinal 
product is more effective, safer or otherwise clinically superior. The 
derogation based on ‘clinical superiority’ in Article 8(3)(c) of 
Regulation 141/2000 has the potential to amount to an almost 
insurmountable hurdle for some researchers.  
In line with the aim of supporting research, development and 
marketing with regard to OMPs, we thus recommend improved 
conditions for a demonstration of ‘clinical superiority’ for similar OMPs. 
Under Article 3(3)(d) of Commission Regulation 847/2000, ‘clinically 
superior’ is defined to mean that a second medicinal product is shown to 
have a significant diagnostic or therapeutic advantage over an authorised 
OMP in at least one of the three specified ways. Each of the three 
specified ways could be addressed to render the provision more suitable 
for the purpose of facilitating the developing and bringing OMPs on the 
EU market.  
First, the specification of ‘greater efficacy’, in Article 3(3)(d)(1), 
refers to direct comparative clinical trials being ‘generally necessary’. 
This should, in our view, be further qualified by an explicit statement to 
 the effect that the nature of those clinical trials should take account of the 
particularities of the products in question, such as limitations on patient 
recruitment.  
Secondly, ‘greater safety in a substantial portion of the target 
population(s)’, in Article 3(3)(d)(2), also refers to direct comparative 
clinical trials being ‘necessary’ in ‘some cases’. Our proposal, on which 
the Commission could usefully seek public and stakeholder input, would 
be to give the benefit of the doubt to a second OMP where (a) it is 
demonstrated to be at least as safe and (b) the CHMP consider it more 
likely than not, according to the standard of a prudently cautious and 
conscientious scientist in the relevant field of research, that the safety of 
the second product is greater. For example, it is generally recognised in 
the literature that a cell-based OMP that is totally animal free and 
manufactured in compliance with GMP is safer than a cell-based OMP 
with xenogeneic components, since the use of animal materials in tissue 
destined for human transplantation bears the risk of eliciting an 
immunologic response and producing interspecies pathogen transfer.
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A prudently cautious and conscientious scientist in the relevant field of 
research would therefore probably assess an animal-free product that is 
manufactured under GMP conditions as more likely than not to be safer.
96
 
In other words, ‘greater safety’ based on the scientific literature might be 
presumed in this example once the second product is demonstrated to be 
at least as safe. This approach would give patient safety the highest 
priority, yet recognise that limitations on patient recruitment to clinical 
trials on OMPs can make it extremely difficult to demonstrate ‘greater 
safety in a substantial portion of the target population(s)’ statistically. If 
any risk to the patient can be minimised by using newly developed 
materials and/or methods to manufacture OMPs, it should be possible for 
such similar OMPs to be placed on the EU market to ensure, in 
accordance with the aim of orphan incentives, that patients suffering from 
rare diseases have access to the same quality of medicinal products as 
any other patient in the EU.  
Thirdly, Article 3(3)(d)(3) refers to ‘exceptional cases’, in which the 
second ‘medicinal product otherwise makes a major contribution to 
diagnosis or to patient care’. This would benefit from specific examples 
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 for similar OMPs.  
For the implementation of our suggestions, we recommend that the 
European Commission should amend Article 3(3)(d) of Commission 
Regulation 847/2000 where necessary and explain the details in the 
Commission Guideline (particularly in section 3.3.2.3). Incorporating the 
details in the Commission Guideline (rather than in the Commission 
Regulation) has the advantage that – in cases of unexpected difficulties or 
major technological advances – the Commission Guideline could be 
amended faster.
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5 Conclusion 
This article has analysed the extent to which an EU marketing 
authorisation of an OMP has an impact on related research. We have 
explained the negative effects of the current 10-year market exclusivity 
provision for researchers/sponsors seeking to obtain a marketing 
authorisation for their product. While defending and retaining that 
provision we have made two proposals: (i) new principles for assessing 
similarity and (ii) improved conditions for a demonstration of ‘clinical 
superiority’ for similar OMPs. 
With regard to the first issue, we have supported the aims of the 
European Commission’s proposals of 29 July 2016. We have, however, 
gone beyond the Commission’s proposals by highlighting specific issues 
arising with regard to the criterion of ‘same therapeutic indication’. We 
demonstrated that in particular in cases of related research where a 
second medicinal product contains a ‘similar active substance’ to that 
contained in an authorised OMP, the therapeutic indication is decisive in 
order to assess whether two medicinal products are similar under 
Article 3(3)(b) of Commission Regulation 847/2000. We argued that in 
cases where there is an overlap of the target populations, the current 
principle of looking at the extent of such overlap in order to establish 
whether two medicinal products are intended for the same therapeutic 
indication should be abandoned, or at least clear guidance on when the 
competent assessing body should consider an overlap significant should 
be introduced. Our preferred proposal is for the competent assessing body 
to focus on the overlap of the target populations itself (instead of the 
extent of the overlap) and conclude that: (i) the two medicinal products 
are intended for the same therapeutic indication where there is overlap of 
the target populations and (ii) the two medicinal products have different 
                                                          
97 For the procedures see Art. 8(4) and (5) of Regulation 141/2000. 
 therapeutic indications where there is no overlap of the target 
populations. 
We also argued that it is difficult for a second applicant of a similar 
medicinal product designated as an OMP to establish that one of the 
derogations in Article 8(3) of Regulation 141/2000 applies. In particular, 
the third derogation based on ‘clinical superiority’, although in the sphere 
of influence of the second applicant, is hard to demonstrate in practice. In 
accordance with the aim of orphan incentives, we have proposed 
clarification to provide improved conditions for a demonstration of 
‘clinical superiority’ in relation to Article 3(3)(d) of Commission 
Regulation 847/2000. 
 
 
